Ling-Ling Zhai1, Peng Wang1, Ling-Yu Zhou1, Jia-Yu Yin1, Qin Tang2, Tin-Juan Zhang1, Yu-Xin Wang1, Dong-Qin Yang1, Jiang Lin1, Zhao-Qun Deng1. 1. The Affiliated People's Hospital of Jiangsu University Zhenjiang 212002, Jiangsu, People's Republic of China. 2. The Affiliated People's Hospital of Jiangsu University Zhenjiang 212002, Jiangsu, People's Republic of China ; The Affiliated Jintan Hospital of Jiangsu University Zhenjiang 212002, Jiangsu, People's Republic of China.
Abstract
BACKGROUND: Dysregulation of miR-675 has been found in a variety of solid tumors. MiR-675 has been suggested as having both oncogenic and tumor suppression properties in cancer. However, there is no evidence whether miR-675 is involved in breast cancer. The objective of this study was to evaluate the expression status of miR-675 and its clinical relevance in breast cancer patients. METHODS: The expression level of miR-675 was detected in 100 breast cancer patients and 38 cancer-free controls using real-time quantitative PCR. The clinicopathological characteristics of miR-675 in breast cancer were also investigated. All statistical analyses were performed using SPSS 20.0. RESULTS: The study showed that miR-675 was significantly up-regulated in breast cancer patients compared with controls (P < 0.01). There was no significant difference in age, lymph nodes stage, ER status and PR status between patients with and without miR-675 over-expression (P > 0.05). The frequency of miR-675 over-expression was higher in the patients of histological grade I-II than in others (50% versus 9%, P = 0.011). The expression level of miR-675 had a high correlation with miR-24/93/98/378 in breast cancer patients. CONCLUSIONS: Taken together, our study demonstrated that miR-675 in formalin-fixed paraffin-embedded (FFPE) tissues might serve as a good source for biomarker discovery and breast cancer validation.
BACKGROUND: Dysregulation of miR-675 has been found in a variety of solid tumors. MiR-675 has been suggested as having both oncogenic and tumor suppression properties in cancer. However, there is no evidence whether miR-675 is involved in breast cancer. The objective of this study was to evaluate the expression status of miR-675 and its clinical relevance in breast cancerpatients. METHODS: The expression level of miR-675 was detected in 100 breast cancerpatients and 38 cancer-free controls using real-time quantitative PCR. The clinicopathological characteristics of miR-675 in breast cancer were also investigated. All statistical analyses were performed using SPSS 20.0. RESULTS: The study showed that miR-675 was significantly up-regulated in breast cancerpatients compared with controls (P < 0.01). There was no significant difference in age, lymph nodes stage, ER status and PR status between patients with and without miR-675 over-expression (P > 0.05). The frequency of miR-675 over-expression was higher in the patients of histological grade I-II than in others (50% versus 9%, P = 0.011). The expression level of miR-675 had a high correlation with miR-24/93/98/378 in breast cancerpatients. CONCLUSIONS: Taken together, our study demonstrated that miR-675 in formalin-fixed paraffin-embedded (FFPE) tissues might serve as a good source for biomarker discovery and breast cancer validation.
Entities:
Keywords:
Biomarkers; breast cancer; formalin-fixed paraffin-embedded; miR-675
Authors: Wing Pui Tsang; Enders K O Ng; Simon S M Ng; Hongchuan Jin; Jun Yu; Joseph J Y Sung; Tim Tak Kwok Journal: Carcinogenesis Date: 2009-11-19 Impact factor: 4.944
Authors: Patrick Scicluna; Stefano Caramuta; Hanna Kjellin; Cheng Xu; Robin Fröbom; Monira Akhtar; Jiwei Gao; Hao Shi; Magnus Kjellman; Malin Almgren; Anders Höög; Jan Zedenius; Tomas J Ekström; Robert Bränström; Weng-Onn Lui; Catharina Larsson Journal: Int J Oncol Date: 2022-09-28 Impact factor: 5.884